Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer

Chen Chin Pen, Che Ming Liu, Cho Chin Lin, Chia Chen Lin, Teng Fu Hsieh, Sajni Josson, Yun Chi He, Leland W K Chung, Keh Liang Lin, Shian Ying Sung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recent evidence has demonstrated that detection of changes in the levels of urinary vascular endothelial growth factor (VEGF) and tissue a disintegrin and metalloproteinase 9 (ADAM9) is effective in determining prostate cancer progression. To evaluate the combined application of VEGF and ADAM9 as early progression markers of lethal phenotypic cancer, quantification of urinary VEGF and tissue ADAM9 expression was studied in patients with late stage prostate cancer. Tissue biopsies were collected during palliative transurethral resection of prostate (TURP) surgery, and urine samples were collected before hormone therapy and 3, 6 and 12 months post-TURP. We observed a nearly 100% correlation between increasing urinary VEGF levels over time and prostate cancer progression, but no correlation was observed when comparing urinary VEGF concentrations at a single time point and cancer progression. In addition, we also observed correlation of increasing ADAM9 nuclear positive staining and lethal phenotypic transition. Statistical analysis revealed that both the increase in urinary VEGF level and the presence of the tissue ADAM9 nuclear staining were significantly correlated with the risk of patients with relapse prostate cancer (P <0.05). Thus, we suggest that combination of detection of changes in urinary VEGF and tissue staining of ADAM9 may be accurate for predicting the mortality of patients with prostate cancer during hormone therapy.

Original languageEnglish
JournalChinese Journal of Physiology
Volume55
Issue number6
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Disintegrins
Metalloproteases
Vascular Endothelial Growth Factor A
Prostatic Neoplasms
Transurethral Resection of Prostate
Staining and Labeling
Hormones
Neoplasms
Urine
Biopsy
Recurrence
Mortality
Therapeutics

Keywords

  • ADAM9
  • Prostate cancer
  • Urine VEGF

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer. / Pen, Chen Chin; Liu, Che Ming; Lin, Cho Chin; Lin, Chia Chen; Hsieh, Teng Fu; Josson, Sajni; He, Yun Chi; Chung, Leland W K; Lin, Keh Liang; Sung, Shian Ying.

In: Chinese Journal of Physiology, Vol. 55, No. 6, 2012.

Research output: Contribution to journalArticle

Pen, Chen Chin ; Liu, Che Ming ; Lin, Cho Chin ; Lin, Chia Chen ; Hsieh, Teng Fu ; Josson, Sajni ; He, Yun Chi ; Chung, Leland W K ; Lin, Keh Liang ; Sung, Shian Ying. / Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer. In: Chinese Journal of Physiology. 2012 ; Vol. 55, No. 6.
@article{30d82a770cb046a3977393c78cea3d44,
title = "Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer",
abstract = "Recent evidence has demonstrated that detection of changes in the levels of urinary vascular endothelial growth factor (VEGF) and tissue a disintegrin and metalloproteinase 9 (ADAM9) is effective in determining prostate cancer progression. To evaluate the combined application of VEGF and ADAM9 as early progression markers of lethal phenotypic cancer, quantification of urinary VEGF and tissue ADAM9 expression was studied in patients with late stage prostate cancer. Tissue biopsies were collected during palliative transurethral resection of prostate (TURP) surgery, and urine samples were collected before hormone therapy and 3, 6 and 12 months post-TURP. We observed a nearly 100{\%} correlation between increasing urinary VEGF levels over time and prostate cancer progression, but no correlation was observed when comparing urinary VEGF concentrations at a single time point and cancer progression. In addition, we also observed correlation of increasing ADAM9 nuclear positive staining and lethal phenotypic transition. Statistical analysis revealed that both the increase in urinary VEGF level and the presence of the tissue ADAM9 nuclear staining were significantly correlated with the risk of patients with relapse prostate cancer (P <0.05). Thus, we suggest that combination of detection of changes in urinary VEGF and tissue staining of ADAM9 may be accurate for predicting the mortality of patients with prostate cancer during hormone therapy.",
keywords = "ADAM9, Prostate cancer, Urine VEGF",
author = "Pen, {Chen Chin} and Liu, {Che Ming} and Lin, {Cho Chin} and Lin, {Chia Chen} and Hsieh, {Teng Fu} and Sajni Josson and He, {Yun Chi} and Chung, {Leland W K} and Lin, {Keh Liang} and Sung, {Shian Ying}",
year = "2012",
doi = "10.4077/CJP.2012.BAA075",
language = "English",
volume = "55",
journal = "Chinese Journal of Physiology",
issn = "0304-4920",
publisher = "Chinese Physiological Society",
number = "6",

}

TY - JOUR

T1 - Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer

AU - Pen, Chen Chin

AU - Liu, Che Ming

AU - Lin, Cho Chin

AU - Lin, Chia Chen

AU - Hsieh, Teng Fu

AU - Josson, Sajni

AU - He, Yun Chi

AU - Chung, Leland W K

AU - Lin, Keh Liang

AU - Sung, Shian Ying

PY - 2012

Y1 - 2012

N2 - Recent evidence has demonstrated that detection of changes in the levels of urinary vascular endothelial growth factor (VEGF) and tissue a disintegrin and metalloproteinase 9 (ADAM9) is effective in determining prostate cancer progression. To evaluate the combined application of VEGF and ADAM9 as early progression markers of lethal phenotypic cancer, quantification of urinary VEGF and tissue ADAM9 expression was studied in patients with late stage prostate cancer. Tissue biopsies were collected during palliative transurethral resection of prostate (TURP) surgery, and urine samples were collected before hormone therapy and 3, 6 and 12 months post-TURP. We observed a nearly 100% correlation between increasing urinary VEGF levels over time and prostate cancer progression, but no correlation was observed when comparing urinary VEGF concentrations at a single time point and cancer progression. In addition, we also observed correlation of increasing ADAM9 nuclear positive staining and lethal phenotypic transition. Statistical analysis revealed that both the increase in urinary VEGF level and the presence of the tissue ADAM9 nuclear staining were significantly correlated with the risk of patients with relapse prostate cancer (P <0.05). Thus, we suggest that combination of detection of changes in urinary VEGF and tissue staining of ADAM9 may be accurate for predicting the mortality of patients with prostate cancer during hormone therapy.

AB - Recent evidence has demonstrated that detection of changes in the levels of urinary vascular endothelial growth factor (VEGF) and tissue a disintegrin and metalloproteinase 9 (ADAM9) is effective in determining prostate cancer progression. To evaluate the combined application of VEGF and ADAM9 as early progression markers of lethal phenotypic cancer, quantification of urinary VEGF and tissue ADAM9 expression was studied in patients with late stage prostate cancer. Tissue biopsies were collected during palliative transurethral resection of prostate (TURP) surgery, and urine samples were collected before hormone therapy and 3, 6 and 12 months post-TURP. We observed a nearly 100% correlation between increasing urinary VEGF levels over time and prostate cancer progression, but no correlation was observed when comparing urinary VEGF concentrations at a single time point and cancer progression. In addition, we also observed correlation of increasing ADAM9 nuclear positive staining and lethal phenotypic transition. Statistical analysis revealed that both the increase in urinary VEGF level and the presence of the tissue ADAM9 nuclear staining were significantly correlated with the risk of patients with relapse prostate cancer (P <0.05). Thus, we suggest that combination of detection of changes in urinary VEGF and tissue staining of ADAM9 may be accurate for predicting the mortality of patients with prostate cancer during hormone therapy.

KW - ADAM9

KW - Prostate cancer

KW - Urine VEGF

UR - http://www.scopus.com/inward/record.url?scp=84868632521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868632521&partnerID=8YFLogxK

U2 - 10.4077/CJP.2012.BAA075

DO - 10.4077/CJP.2012.BAA075

M3 - Article

C2 - 23286446

AN - SCOPUS:84868632521

VL - 55

JO - Chinese Journal of Physiology

JF - Chinese Journal of Physiology

SN - 0304-4920

IS - 6

ER -